Comparison of the treatment with paroxetine and reboxetine in panic disorder: A randomized, single-blind study

Pharmacopsychiatry

Volumn 37, Issue 5, 2004, Pages 206-210

  Bertani, Angelo ^a,b   Perna, G ^a   Migliarese, G ^a   Di Pasquale, D ^a   Cucchi, M ^a   Caldirola, D ^a   Bellodi, L ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; REBOXETINE;

ACADEMIC ACHIEVEMENT; ADULT; AGORAPHOBIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEAR QUESTIONNAIRE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; ONSET AGE; PANIC; PANIC ASSOCIATED SYMPTOMS SCALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEXUAL DYSFUNCTION; SHEEHAN DISABILITY SCALE; SINGLE BLIND PROCEDURE; SOMNOLENCE; SWEATING; TACHYCARDIA; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; FEMALE; HUMANS; MALE; MORPHOLINES; PANIC DISORDER; PAROXETINE; PSYCHOMETRICS; SEROTONIN UPTAKE INHIBITORS; SINGLE-BLIND METHOD;

EID: 4644307179     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832593     Document Type: Article

References (30)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington DC: APA, 1994
2. Argyle N, Deltito J, Allerup P et al. The Panic-Associated Symptom Scale: measuring the severity of panic disorder. Acta Psychiatr Scand 1991; 83: 20-26
3. Ballenger JC, Wheadon DE, Steiner M et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155: 36-42
4. Belzung C, El Hage W, Moindrot N et al. Behavioral and neurochemical changes following predatory stress in mice. Neuropharmacology 2001; 41: 400-408
5. Boerner RJ, Moller HJ. The importance of new antidepressants in the treatment of anxiety/depressive disorders. Pharmacopsychiatry 1999; 32: 119-126
6. Brown MT, Dubini A, Di Nicolo P. Double-blind, placebo-controlled study of reboxetine in panic disorder. Abstract presented at the symposium "Norepineprine": New Vistas for an old neurotransmitter. Key west, FL
7. Cassano GB, Petracca A, Perugi G et al. Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine. J Affect Disord 1988; 14: 123-127
8. Cole BJ, Robbins TW. Dissociable effects of lesions to the dorsal or ventral noradrenergic bundle on the acquisition, performance, and extinction of aversive conditioning. Behav Neurosci 1987; 101: 476-488
9. Den Boer JA, Westenberg HG. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988; 3: 59-74
10. Dunner D, Kumar R. Paroxetine: a review of clinical experience. Pharmacopsychiatry 1998; 31: 89-101
11. Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993; 13: 321-326
12. Humble M, Wistedt B. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders. Int Clin Psychopharmacol 1992; 6 (Suppl 5): 21-39
13. Johnson MR, Lydiard RB. The neurobiology of anxiety disorders. Psychiatr Clin North Am 1995; 18: 681-725
14. Klein DF. Delineation of two-responsive anxiety syndromes. Psychopharmacologia 1964; 5: 397-408
15. Leon AC, Shear MK, Portera L et al. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 1992; 27: 78-82
16. Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther 1979; 17: 263-267
17. Michael A, Andrews S. Paroxetine-induced vaginal anaesthesia. Pharmacopsychiatry 2002; 35: 150-151
18. Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 1999; 7: 69-84
19. Masi G, Toni C, Mucci M et al. Paroxetine in child and adolescent outpatients with panic disorder. J Child Adolesc Psychopharmacol 2001; 11: 151-157
20. Mavissakalian MR, Perel JM, Talbott-Green M et al. Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. Biol Psychiatry 1998; 43: 848-854
21. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992; 12: 251-261
22. Montejo AL, Llorca G, Izquierdo J et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62: 10-21
23. Perna G, Bertani A, Caldirola D et al. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2001; 34: 85-90
24. Sasson Y, Iancu I, Fux M et al. A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 1999; 9: 191-196
25. Seedat S, van Rheede van Oudtshoorn E, Muller JE et al. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol 2003; 18: 279-284
26. Sheehan DV, Harnett-Sheehan K. The role of SSRIs in panic disorder. J Clin Psychiatry 1996; 57 (Suppl 10): 51-58; discussion 59-60
27. Sheehan DV, Lecrubier Y, Janavs J et al. Mini International Neuropsychiatric Interview. MINI, Paris/Tampa: 1994
28. Sullivan GM, Coplan JD, Kent JM et al. The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biol Psychiatry 1999; 46: 1205-1218
29. Versiani M, Cassano G, Perugi G et al. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002; 63: 31-37
30. Wong EH, Sonders MS, Amara SG et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 2000; 47: 818-829